CoChat

The effect of caffeine on cognitive performance is influenced by CYP1A2 but not ADORA2A genotype, yet neither genotype affects exercise performance in healthy adults

Open access
Carswell, Alexander T., Howland, Kevin, Martinez-Gonzalez, Borja, Baron, Pauline, Davison, Glen · 2020 · European Journal of Applied Physiology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Purpose: To determine the influence of two commonly occurring genetic polymorphisms on exercise, cognitive performance, and caffeine metabolism, after caffeine ingestion. Methods: Eighteen adults received caffeine or placebo (3 mg kg−1) in a randomised crossover study, with measures of endurance exercise (15-min cycling time trial; 70-min post-supplementation) and cognitive performance (psychomotor vigilance test; PVT; pre, 50 and 95-min post-supplementation). Serum caffeine and paraxanthine were measured (pre, 30 and 120-min post-supplementation), and polymorphisms in ADORA2A (rs5751876) and CYP1A2 (rs762551) genes analysed. Results: Caffeine enhanced exercise performance (P < 0.001), but effects were not different between participants with ADORA2A ‘high’ (n = 11) vs. ‘low’ (n = 7) sensitivity genotype (+ 6.4 ± 5.8 vs. + 8.2 ± 6.8%), or CYP1A2 ‘fast’ (n = 10) vs. ‘slow’ (n = 8) metabolism genotype (+ 7.2 ± 5.9 vs. + 7.0 ± 6.7%, P > 0.05). Caffeine enhanced PVT performance (P < 0.01). The effect of caffeine was greater for CYP1A2 ‘fast’ vs. ‘slow’ metabolisers for reaction time during exercise (− 18 ± 9 vs. − 1.0 ± 11 ms); fastest 10% reaction time at rest (− 18 ± 11 vs. − 3 ± 15 ms) and lapses at rest (− 3.8 ± 2.7 vs. + 0.4 ± 0.9) (P < 0.05). There were no PVT differences between ADORA2A genotypes (P > 0.05). Serum caffeine and paraxanthine responses were not different between genotypes (P > 0.05). Conclusion: Caffeine enhanced CYP1A2 ‘fast’ metabolisers’ cognitive performance more than ‘slow’ metabolisers. No other between-genotype differences emerged for the effect of caffeine on exercise or cognitive performance, or metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00421-020-04384-8

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic of experimental procedures. PVT psychomotor vigilance test; Syringe icon represents venous blood sample collected pre-supplementation, and 30 min and ~ 120 min post-supplementation
Fig. 1 Schematic of experimental procedures. PVT psychomotor vigilance test; Syringe icon represents venous blood sample collected pre-supplementation, and 30 min and ~ 120 min post-supplementationCC BY · PubMed Central
Fig. 2 Caffeine–placebo change scores for total work performed during 15-min cycling time trial. a, b ADORA2A genotype ‘high’ (filled bars) and ‘low’ sensitivity to caffeine (open bars). c, d CYP1A2 genotype ‘fast’ (filled bars) and ‘slow’ caffeine metabolisers (open bars). a, c Bars represent individual participants. b, d Data are mean ± SD
Fig. 2 Caffeine–placebo change scores for total work performed during 15-min cycling time trial. a, b ADORA2A genotype ‘high’ (filled bars) and ‘low’ sensitivity to caffeine (open bars). c, d CYP1A2 genotype ‘fast’ (filled bars) and ‘slow’ caffeine metabolisers (open bars). a, c Bars represent individual participants. b, d Data are mean ± SDCC BY · PubMed Central
Fig. 3 Psychomotor vigilance test reaction time for caffeine (filled squares) and placebo trials (open squares) measured at rest pre-supplementation, during exercise, and at rest post-supplementation. Data are mean ± SD. **P < 0.01, vs. placebo; †††P < 0.001, vs. pre
Fig. 3 Psychomotor vigilance test reaction time for caffeine (filled squares) and placebo trials (open squares) measured at rest pre-supplementation, during exercise, and at rest post-supplementation. Data are mean ± SD. **P < 0.01, vs. placebo; †††P < 0.001, vs. preCC BY · PubMed Central
Fig. 4 Psychomotor vigilance test caffeine–placebo change scores for a reaction time, b fastest 10% reaction time, c response speed, d slowest 10% response speed, and e number of lapses during exercise and at rest post-supplementation. Participants are categorised according to ADORA2A genotype: ‘high’ (filled bars) or ‘low’ sensitivity to caffeine (open bars). Data are mean ± SD
Fig. 4 Psychomotor vigilance test caffeine–placebo change scores for a reaction time, b fastest 10% reaction time, c response speed, d slowest 10% response speed, and e number of lapses during exercise and at rest post-supplementation. Participants are categorised according to ADORA2A genotype: ‘high’ (filled bars) or ‘low’ sensitivity to caffeine (open bars). Data are mean ± SDCC BY · PubMed Central
Fig. 5 Psychomotor vigilance test caffeine–placebo change scores for a reaction time, b fastest 10% reaction time, c response speed, d slowest 10% response speed, and e number of lapses during exercise and at rest post-supplementation. Participants are categorised according to CYP1A2 genotype: ‘fast’ (filled bars) or ‘slow’ caffeine metabolisers (open bars). Data are mean ± SD. #P < 0.05 and ##P < 0.01, between genotypes
Fig. 5 Psychomotor vigilance test caffeine–placebo change scores for a reaction time, b fastest 10% reaction time, c response speed, d slowest 10% response speed, and e number of lapses during exercise and at rest post-supplementation. Participants are categorised according to CYP1A2 genotype: ‘fast’ (filled bars) or ‘slow’ caffeine metabolisers (open bars). Data are mean ± SD. #P < 0.05 and ##P < 0.01, between genotypesCC BY · PubMed Central
Fig. 6 Serum a caffeine, b paraxanthine, and c the paraxanthine:caffeine ratio for caffeine and placebo trials measured pre-supplementation, and 30-min and ~ 120-min post-supplementation. Data are mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001, vs. placebo; ‡‡P < 0.01, vs. 30 min; †P < 0.05 and †††P < 0.001, vs. pre
Fig. 6 Serum a caffeine, b paraxanthine, and c the paraxanthine:caffeine ratio for caffeine and placebo trials measured pre-supplementation, and 30-min and ~ 120-min post-supplementation. Data are mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001, vs. placebo; ‡‡P < 0.01, vs. 30 min; †P < 0.05 and †††P < 0.001, vs. preCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 61

Metadata

Authors
Carswell, A. T., Howland, K., Martinez-Gonzalez, B., Baron, P., & Davison, G.
Affiliations
University of Kent (GB)
Corresponding author
Davison, Glen
Venue
European Journal of Applied Physiology
Published
2020-04-30
Volume
120
Issue
7
Pages
1495-1508
ISSN
  • 0020-9376 (ISSN-L)
  • 1439-6319
  • 1439-6327
OpenAlex
W3021620141
Cited by
61
References
36
Citations by year
2026: 5 · 2025: 12 · 2024: 10 · 2023: 10 · 2022: 9 · 2021: 7 · 2020: 7
FWCI
4.95
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Applied Physiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kent Academic Repository (University of Kent) (acceptedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
caffeine, CYP1A2, adenosine A2A receptor, genetic polymorphism, caffeine metabolism, exercise performance, cognitive performance, psychomotor vigilance, paraxanthine, endurance cycling, caffeine sensitivity, healthy adults
MeSH terms
Adult, Caffeine, Female, Genotype, Humans, Male, Exercise, Cytochrome P-450 CYP1A2, Receptor, Adenosine A2A, Young Adult, Performance-Enhancing Substances

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of caffeine on cognitive performance is influenced by CYP1A2 but not ADORA2A genotype, yet neither genotype affects exercise performance in healthy adults. https://app.cochat.ai/papers/10.1007/s00421-020-04384-8
The paper
Carswell, A. T., Howland, K., Martinez-Gonzalez, B., Baron, P., & Davison, G. (2020). The effect of caffeine on cognitive performance is influenced by CYP1A2 but not ADORA2A genotype, yet neither genotype affects exercise performance in healthy adults. European Journal of Applied Physiology. https://doi.org/10.1007/s00421-020-04384-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.